NodThera's NLRP3 Inhibitor Ruvonoflast Shows Promising Anti-Inflammatory Effects in Cardiovascular Risk Patients
核心洞察
NodThera (搜索) published first peer-reviewed clinical data in JACC demonstrating that ruvonoflast (搜索), an oral NLRP3 (搜索) inhibitor, reduced hsCRP (搜索) by 82% in patients at high cardiovascular risk.
The randomized, placebo-controlled study showed 76% of ruvonoflast (搜索)-treated patients achieved hsCRP (搜索) levels below 2 mg/L, a threshold associated with 25% MACE reduction in landmark trials.
Ruvonoflast (搜索) significantly reduced multiple thrombo-inflammatory biomarkers including IL-6, fibrinogen, and Lp(a), with effects that were rapid, sustained, and reversible.
NodThera (搜索) has published the first peer-reviewed clinical data demonstrating significant anti-inflammatory effects of its oral NLRP3 (搜索) inhibitor ruvonoflast (搜索) in patients with cardiometabolic disease. The data, published in the Journal of the American College of Cardiology (JACC) and presented at the 94th European Atherosclerosis Society Congress in Athens, Greece, represents a potential breakthrough in targeting inflammation as a cardiovascular risk factor.
Clinical Trial Results Show Dramatic Biomarker Reductions
The randomized, double-blind, placebo-controlled study (NCT06129409) evaluated ruvonoflast (搜索)'s effects on inflammation in participants at risk of cardiovascular disease. The results demonstrated that ruvonoflast achieved an 82% reduction in high-sensitivity C-reactive protein (hsCRP (搜索)), a well-validated biomarker of inflammation associated with atherosclerotic cardiovascular disease (ASCVD) events.
Notably, 76% of ruvonoflast (搜索)-treated patients achieved hsCRP (搜索) levels below 2 mg/L, the threshold shown to be associated with a 25% reduction in major adverse cardiovascular events (MACE) in the landmark CANTOS cardiovascular outcome trial. This achievement suggests significant potential for cardiovascular event reduction.
Broad Anti-Inflammatory and Anti-Thrombotic Effects
Beyond hsCRP (搜索) reduction, ruvonoflast (搜索) demonstrated significant effects on multiple thrombo-inflammatory biomarkers, including interleukin-6 (IL-6), fibrinogen, and lipoprotein(a). These comprehensive effects underscore the drug's anti-inflammatory, anti-thrombotic, and metabolic potential through upstream inhibition of the NLRP3 (搜索)/IL-1 (搜索)/IL-6/IL-18 (搜索) inflammation pathway.
The study revealed that ruvonoflast (搜索)'s effects on hsCRP (搜索) were rapid, sustained, and readily reversible, representing a potentially key differentiator versus injectable biologics currently in development for cardiovascular inflammation.
Expert Commentary on Anti-Inflammatory Cardiovascular Therapy
"Inflammation is a causal, modifiable risk factor for atherosclerotic disease," said Prof. Paul Ridker of Harvard Medical School. "Our field now stands at an important inflection point, with multiple anti-inflammatory therapies in late-stage development. If also proven successful at reducing cardiovascular events, oral anti-inflammatory options that are scalable would be a welcome addition to our growing cardiovascular armamentarium."
Clinical Development Pathway and Future Trials
The published data, along with results from NodThera (搜索)'s previously published trial in patients with neuroinflammation, informed the design of two large ongoing Phase 2 trials: RESOLVE-1 and RESOLVE-2, which represent the largest and longest NLRP3 (搜索) clinical trials to date.
Dr. Jyothis George, Chief Medical Officer of NodThera (搜索), emphasized the study's significance: "This study in patients with elevated residual inflammation establishes the potential of ruvonoflast (搜索) as a selective anti-inflammatory therapy for people across the cardio-kidney-metabolic spectrum with elevated residual inflammation who remain at an increased risk for adverse cardiovascular outcomes."
NodThera (搜索) is preparing to advance ruvonoflast (搜索) into Phase 3 cardiometabolic development following the RESOLVE-1 trial readout expected in Q3 2026. The company expects to commence a Phase 3 registrational study of ruvonoflast in the first half of 2027.
Company Pipeline and Investment
NodThera (搜索), described as the leading clinical-stage NLRP3 (搜索) company, is developing a portfolio of brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of both cardiometabolic and neurologic diseases. The company is also advancing NT-0150 (搜索) for treatment of neuroinflammatory diseases, with Phase 1 results expected in the second half of 2026.
The Boston-based company, with an R&D base in the UK, is backed by top-tier investors including Blue Owl Capital, Novo Holdings, F-Prime Capital, 5AM Ventures, Sofinnova Partners, Epidarex Capital, and Sanofi Ventures.